Patients of interest (metastatic CRPCa) | Control patients (metastatic PCa) | Healthy participants | |
---|---|---|---|
Inclusion criteria | 70-years old or more | 70-years old or more | 70-years old or more |
Patient must have a metastatic CRPCa | Patient with metastatic prostate cancer without resistance to castration | Man with no history of cancer | |
Patient must have been already treated with first generation of ADT | Patient must have already started a first generation of ADT at least since 3 months | - | |
Patient must be candidate for a treatment by a NGHT (with abiraterone acetate or enzalutamide), in combination with ADT | - | - | |
Treatment with biphosphonates is authorized | - | - | |
Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion | Patient must have not received chemotherapy except one line per Docetaxel for hormono-sensitive situation and which must be completed for a least 18 months before inclusion | - | |
OMS 0–2 | OMS 0–2 | Health status consistent with the participation to the study | |
Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤3) | Patient must be asymptomatic or pauci-symptomatic (with pain control, Visual Analog Scale ≤3) | - | |
No known brain metastasis | No known brain metastasis | - | |
At least on level 3 (end of primary schools) of the Barbizet scale | At least on level 3 (end of primary schools) of the Barbizet scale | At least on level 3 (end of primary schools) of the Barbizet scale | |
Exclusion criteria | Neurological sequelae of traumatic brain injury, stroke, multiple sclerosis, epilepsy, neuro-degenerative disease… | ||
Personality disorders and known progressive psychiatric disorder | |||
Drug use and/or heavy drinking | |||
Assessed to be unable or unwilling to comply with the requirements of the protocol |